Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase ...

Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated ...

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab ...

In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs). ≥90 percent mean LDL-C ...

Very high levels are even more dangerous than better-known risks for heart-attack and stroke. “In individuals who don’t have heart disease, it seems it is equivalent to having two other modifiable ...

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.

Rezdiffra leads MASH as TAM expands; growth for 2–3 years but big competition risks. Click for more on MDGL here.

High blood pressure is incredibly common, affecting nearly half of U.S. adults. It’s also one of the biggest risk factors for ...

Nourish, the country’s largest dietitian-led metabolic health clinic, today announced its $100 million Series C, bringing total funding to $215 million. The round was led by Menlo Ventures, with ...

Detailed price information for Newamsterdam Pharma Company N.V. (NAMS-Q) from The Globe and Mail including charting and trades.

Quick Read Viking Therapeutics (VKTX) has a dual GLP-1/GIP agonist in Phase 3 with 4,500+ patients enrolled and oral formulations showing 12.2% body weight reduction, offering a strategic acquisition ...